Abcam, ab92478, Anti-Apolipoprotein A II/ApoA-II antibody [EPR2913]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal Apolipoprotein A II/ApoA-II antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 11 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR2913,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.05% Sodium azideConstituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-II (also known as ApoA-II or Apolipoprotein A2) is a pivotal protein component of high-density lipoproteins (HDL) in the plasma. It is encoded by the APOA2 gene in humans and displays a molecular mass of approximately 17.4 kDa. Apolipoprotein A-II is primarily expressed in the liver and secreted into the bloodstream where it plays a direct role in lipid metabolism. Its structural composition includes a highly amphipathic α-helical structure that facilitates interaction with lipids aiding in lipoprotein formation and stability.
Biological function summary
Apolipoprotein A-II serves as a significant regulator of HDL metabolism and lipid transport. It is an integral part of HDL particles contributing to their stability and function. Apolipoprotein A-II influences lecithin-cholesterol acyltransferase (LCAT) activity which affects cholesterol esterification. Although less studied than its counterpart Apolipoprotein A-I ApoA-II's interaction with lipids and proteins such as CETP (cholesteryl ester transfer protein) suggests its involvement in lipid exchange and reverse cholesterol transport processes.
Pathways
Apolipoprotein A-II impacts the reverse cholesterol transport pathway and lipid metabolic processes. ApoA-II works closely with its relative Apolipoprotein A-I both part of the same HDL complex. Together they play essential roles in maintaining cholesterol homeostasis and promoting cholesterol efflux from cells back to the liver. The mechanism by which it modulates the function of lipoprotein lipase and hepatic lipase further implicates its role in lipid metabolism and energy balance processes.
Dysfunction or abnormal levels of Apolipoprotein A-II have associations with cardiovascular diseases and metabolic syndromes. Altered ApoA-II levels correlate with an increased risk of atherosclerosis as its imbalance can drive perturbations in HDL composition and function. Moreover research links Apolipoprotein A-II with insulin resistance linking it with ApoA-I imbalanced lipid transport and metabolism in obesity and diabetes contexts. Understanding these connections may guide therapeutic strategies targeting ApoA-II to mitigate the risks and progression of these disorders.